Sneak peek into our upcoming report
We are excited to give you a sneak peek into our upcoming report on Prescription Digital Therapeutics.
In 2018, we released our first report on Digital Therapeutics (DTx), aiming to get behind the hype and dig into the DTx landscape, business models, regulation, reimbursement, evidence, and adoption. In the past two years, a lot has happened. A wide variety of companies have co-opted the term “digital therapeutics” to describe their digital health offerings. This report seeks to cut through some of that noise by focusing on a smaller subset of this group: prescription digital therapeutics (PDT).
We are excited to announce that for our 2021 PDT report, we are collaborating with Brian Dolan of Exits & Outcomes (E&O). E&O is a digital health research and media company led by Brian, who also founded MobiHealthNews back in 2008.
The objective of this HealthXL- E&O Report is to deep dive into one subsegment of DTx that has enormous potential: prescription products. We shine a light on clinical validation, adoption, investments, reimbursement and regulation.
This report contains key examples of PDT applications, industry implications and a critical viewpoint of the current reality of the DTx environment and those which must be addressed in order to truly deliver on the DTx promise in terms of optimized health outcomes.
What can you expect to see?
Investment / Solutions Landscape
We examine how the investment landscape for PDTs has changed over 2018-2020. It is clear that COVID-19 has hugely increased investments/partnerships within the digital health space, PDTs included! The top funded PDT company of 2020 was Biofourmis, obtaining a whopping $100 million in investments.
Business Models and Pricing
Business models and pricing for digital therapeutics are some of the most sought after details among large corporations, investors and startups alike. In this section of the report we outline different PDT business models which include those that follow the more traditional pharmaceutical pathways to sell their products, and newly emerging models which are leveraging telemedicine to facilitate D2C access. We also take a look at the pricing of PDTs which are currently available on the market.
Clinical and Economic Outcomes
Only 27% of PDTs have published RCTs to validate their product offerings. We compare and contrast the current frameworks that support the validation of PDTs [NICE, FDA, TGA, DIGA], and dig into the rigor of evidence provided for these products vs traditional pharmaceutical agents. We also discuss the use of digital endpoints (or lack thereof) in the validation of these products.
Regulatory Environment, Reimbursement and Prescription Pathways
The report digs deep into the regulatory environment and prescription pathways for PDTs in both the US and the EU. We also assess the reimbursement landscape for PDTs across the globe - while developments in the US remain thin, the EU and Japan appear to be leading the charge in the reimbursement space.
.png)
Adoption and Enablement
Prescription capabilities remain a key challenge in the adoption of PDTs, although Germany and Belgium are spearheading change within this space. In the report we take a deep dive into the adoption and enablement of PDTs, fleshing out regional differences and highlighting companies that are shaking up the distribution chain.
The Future of PDT
PDTs are quickly emerging as one of the most spoken about areas of digital health, although it would appear that many barriers remain for the widespread adoption of these technologies. What needs to happen in politics, within the FDA, within PBMs, in the minds of physicians and consumers to move the needle? We gaze into the crystal ball.
